DermTech appoints chief compliance officer and senior vice president of research and development

LA JOLLA, Calif.–(BUSINESS WIRE)–DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a noninvasive skin genomics platform, has appointed two new members to of its management team. Jennifer Eilemberg has been appointed chief compliance officer and will oversee the company’s compliance with laws, regulatory requirements, and stringent internal policies and procedures. Steven Stone has assumed the role of Senior Vice President of Research and Development and will guide the advancement of DermTech’s noninvasive skin genomics platform and its diverse product portfolio.

“We are building an exceptional team of accomplished life sciences and healthcare leaders to lead the company as we contemplate important operational milestones,” said John Dobak, MD, CEO of DermTech. “Jennifer and Steve both have excellent backgrounds in their respective professions and we are delighted to have them on our team.”

Ms. Eilemberg is an accomplished healthcare law executive with more than 20 years of experience in positions of increasing responsibility in transactional and regulatory healthcare and corporate matters. She has extensive experience in the areas of Laboratory Healthcare, U.S. Food and Drug Administration (FDA), Federal Stark and Anti-Kickback Law Compliance, HIPAA/HITECH Compliance, Reimbursement and Medicare/Medicaid enrollment, state healthcare/professional regulatory compliance, payer/PBM contracts, mergers and acquisitions, and a wide range of commercial transactions. She has provided legal advice and representation before regulatory agencies including the Department of Justice, HHS Office of Inspector General, HHS Office for Civil Rights, Board of Medicine and Board of Pharmacy (multi-state) , the Federal Trade Commission, the FDA and the Drug Enforcement Administration. She has also served as General Counsel and Chief Compliance Officer for several healthcare companies. Ms. Eilemberg is a member of the American Health Lawyers Association and a member of the bars of New Jersey, Pennsylvania and Florida, as well as a registered in-house counsel in California.

Dr. Stone is a seasoned life science executive with significant experience in the development of molecular diagnostics. He was previously vice president of Kidney Care at CareDx, leading a team that oversaw the research and development of several kidney care test offerings. For 25 years, Dr. Stone held positions of increasing responsibility at Myriad Genetics, including as Vice President of Cancer Genomics, where his group was responsible for the development of a molecular prognostic test for newly diagnosed prostate cancer. diagnosed (Prolaris). At Myriad, he participated in the discovery and characterization of several important cancer genes, including BRCA1 and p16. Dr. Stone earned his Ph.D. in genetics from the University of Minnesota. He is the author of over 45 peer-reviewed publications and 10 US patents.

About Derma Tech

DermTech is a leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, made possible by its non-invasive skin genomics platform. DermTech’s mission is to improve the lives of millions of people by providing non-invasive, precision dermatology solutions that enable individualized care. DermTech provides genomic analysis of non-invasively collected skin samples using its smart stickersMT. DermTech markets and develops products that facilitate the early detection of skin cancers and develops products that assess inflammatory diseases and personalize drug treatments. For more information, please visit DermTech.

Forward-looking statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. DermTech’s expectations, estimates and projections may differ from its actual results and, accordingly, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect”, “estimate”, “project”, “budget”, “expect”, “anticipate”, “intend”, “plan”, “may”, “will” , “could”, “should”, “believes”, “predicts”, “potential”, “continues” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, but are not limited to, expectations and assessments regarding: performance, patient benefits, cost-effectiveness, commercialization and adoption of DermTech’s products and the market opportunity for such products, DermTech’s positioning and potential revenue growth, financial outlook and future financial performancestages of operation, implications and interpretations of any study results, evaluation and judgments of the skills and experiences of new members of DermTech’s management team, and expectations regarding their future contributions to DermTech , and DermTech’s ability to develop its product offerings and developing products under development. These forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from expected results. Most of these factors are beyond DermTech’s control and are difficult to predict. Factors that could cause such differences include, but are not limited to: (1) the outcome of any legal proceedings that may be brought against DermTech; (2) DermTech’s ability to obtain additional financing to develop and commercialize its products; (3) the existence of favorable or unfavorable clinical guidelines for DermTech’s tests; (4) reimbursement of DermTech tests by Medicare and private payers; (5) the ability of patients or healthcare providers to obtain sufficient coverage or reimbursement for DermTech’s products; (6) DermTech’s ability to grow, manage growth and retain key employees; (7) changes in applicable laws or regulations; (8) market adoption and demand for DermTech’s products and services, as well as the possibility that DermTech may be adversely affected by other economic, business and/or competitive factors; and (9) other risks and uncertainties included in the “Risk Factors” section of DermTech’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”), and other documents filed or to be filed by DermTech with the SEC, including any subsequent filings. DermTech cautions that the above list of factors is not exclusive. You should not place undue reliance on forward-looking statements, which speak only as of the date made. DermTech neither undertakes nor accepts any obligation or undertaking to issue updates or revisions to any forward-looking statement to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based. .